3-羟基-5-甲基-2-苯并呋喃-1(3H)-酮 | 63113-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 3-羟基-5-甲基-2-苯并呋喃-1(3H)-酮
• 英文名称: 3-Hydroxy-5-methylphthalid
• 英文别名: 5-Methylphthalaldehydsaeure；3-hydroxy-5-methylisobenzofuran-1(3H)-one；3-Hydroxy-5-methyl 3H-isobenzofuran-1-one；3-hydroxy-5-methyl-3H-2-benzofuran-1-one
• CAS: 63113-00-8
• 化学式: C₉H₈O₃
• 分子量: 164.161
• InChiKey: AFZXLLRTYQQFRL-UHFFFAOYSA-N

物化性质

• 沸点：
  380.7±42.0 °C(Predicted)
• 密度：
  1.375±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  3-羟基-5-甲基-2-苯并呋喃-1(3H)-酮 在 sodium hydroxide 作用下， 以 甲醇 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 1.53h， 生成 2-(2-Carboxymethyl-5-methylbenzyliden)-4-methylindan-1-on
  参考文献：
  名称：

  Aromatische Spirane, 23. Mitt.: Darstellung von unsymmetrisch substituierten Dimethyl-2,2?-Spirobiindan-1,1?-dionen

  摘要：

  Both spirodiketones 7 and 8 were obtained as a mixture (56:44) by treatment of dicarbonic acid 5 with polyphosphoric acid (PPA). 5 was accessible from dimethylester 3, synthesized by retro-Claisen reaction between 1 and 2. In the same way, 30 was obtained via 27. The preparation of the pure spiro compounds 7 and 8, resp., was achieved by aldol reaction between 9 and 10 or 9 and 16, resp. Short treatment of the resulting compounds 11 and 17 with diazomethane yielded the methylbenzoates 12 and 18. Prolonged reaction (several hours) gave the pyrazole compounds 14 and 19, resp., which were also obtained (several days) from phthalides 14 and 20. The latter were formed from the benzylidene compounds 11 and 17, resp., by heating. 11 and 17 (after hydrogenation to 15a and 21a) were cyclized either with PPA or thermically to the spiro compounds 7 and 8. The main product 20 was cyclized thermically to 8 after reduction with zinc to a mixture of 21a and 8 (20:75).

  DOI：

  10.1007/bf00810885
• 作为产物：
  描述：

  5-(bromomethyl)-1,3-dihydroisobenzofuran-1-one 在 palladium on activated charcoal calcium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 水 、 氢气 作用下， 以 1,4-二氧六环 为溶剂， 反应 49.0h， 生成 3-羟基-5-甲基-2-苯并呋喃-1(3H)-酮
  参考文献：
  名称：

  Aromatische Spirane, 21. Mitt: Darstellung von Methylphthalaldehyds�uren und ihren Ethylund Methylestern als Synthone f�r Synthesen von methylierten 2,2?-Spirobiindandionen

  摘要：

  The isomeric methyl phthalaldehydic acids 11 were obtained from phthalides 4 by bromation (NBS) to the 3-bromo derivatives 7 and subsequent hydrolysis with water. 4 in turn were accessible from dimethyl methyl benzoates 1 by dibromination with NBS and subsequent thermical cyclization to the bromo derivatives 3 which, on catalytic dehalogenation, afforded the phthalides 4. Reaction of 11 with methanol or ethanol gave the pseudo-esters 13 and 14, resp. Short treatment of 11 with diazomethane on the other hand yielded the methyl formyl benzoates 15b to 15e. Prolonged reaction (several hours) gave the oxiranyl compounds 17; in addition, the acetonyl derivatives 18 were also found, obviously formed by a double methylene insertion into 15. All reactions proceeded with good to excellent yields.

  DOI：

  10.1007/bf00807401

文献信息

• Chiral Bicyclic Imidazole‐Catalyzed Acylative Dynamic Kinetic Resolution for the Synthesis of Chiral Phthalidyl Esters
  作者：Muxing Zhou、Tatiana Gridneva、Zhenfeng Zhang、Ende He、Yangang Liu、Wanbin Zhang

  DOI：10.1002/anie.202012445

  日期：2021.1.18

  Utilizing a chiral bicyclic imidazole organocatalyst and adopting a continuous injection process, an alternative route has been developed for the efficient synthesis of chiral phthalidyl ester prodrugs via dynamic kinetic resolution of 3‐hydroxyphthalides through enantioselective acylation (up to 99 % ee). The computational studies suggest a general base catalytic mechanism differing from the widely

  利用手性双环咪唑有机催化剂并采用连续注射工艺，已开发出另一种途径，可通过对映选择性酰化作用（3-99％ee）动态动力学拆分3-羟基邻苯二酚来有效合成手性邻苯二甲酸酯基前药。计算研究表明，一般的基础催化机理不同于广泛接受的亲核催化机理。关键过渡态的结构分析表明，催化剂与底物之间的CH-π相互作用而不是先前考虑的阳离子/π-π相互作用是引起观察到的立体控制的主要因素。
• N-heterocyclic inhibitors of TNF-alpha expression
  申请人：——

  公开号：US20020065270A1

  公开（公告）日：2002-05-30

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: 1 Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.

  抑制 p38 激酶从而阻断细胞因子产生的 N-杂环化合物已被披露。在一种实施例中，本发明的化合物由式 I 表示。还披露了利用本发明化合物的生产方法、药物组合物以及治疗与不当 p38 激酶活性或 TNF-α 表达相关的疾病的方法。
• N- heterocyclic inhibitors of TNF-alpha expression
  申请人：——

  公开号：US20020137747A1

  公开（公告）日：2002-09-26

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: 1 Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.

  揭示了通过抑制p38激酶阻断细胞因子产生的N-杂环化合物。在一种实施例中，本发明的化合物由式I表示。还揭示了利用本发明的化合物生产方法、制药组合物以及治疗与不当p38激酶活性或TNF-α表达相关的疾病的方法。
• N-heterocyclic inhibitors of TNF-α expression
  申请人：Moriarty Kevin Joseph

  公开号：US06906067B2

  公开（公告）日：2005-06-14

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

  本发明揭示了通过抑制p38激酶来阻断细胞因子产生的N-杂环化合物。在一个实施例中，本发明的化合物由式I表示。还公开了利用本发明的化合物治疗与不当p38激酶活性或TNF-α表达相关的疾病的方法、制备方法和药物组合物。
• [EN] N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION<br/>[FR] INHIBITEURS N-HETEROCYCLIQUES DE L'EXPRESSION DE TNF-ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003002542A1

  公开（公告）日：2003-01-09

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I). Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-a expression utilizing compounds of the present invention are also disclosed.

  本发明揭示了一种通过抑制p38激酶来阻止细胞因子产生的N-杂环化合物。在一种实施例中，本发明的化合物由式(I)表示。本发明还揭示了利用本发明的化合物生产方法、制药组合物以及治疗与不适当的p38激酶活性或TNF-a表达相关的疾病的方法。